H.C. Wainwright lowered the firm’s price target on Novocure (NVCR) to $39 from $42 and keeps a Buy rating on the shares. The company’s Q4 revenue growth highlights continued positive momentum for Optune Gio, the analyst tells investors in a research note. The firm reduced lung cancer estimates for Novocure.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure reports preliminary Q4 revenue $174.4M, consensus $168.93M
- Novocure price target lowered to $20 from $22 at Evercore ISI
- NovoCure’s Strategic Leadership and Product Developments Drive Buy Rating
- NovoCure Appoints Frank Leonard as New CEO
- Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds